DTCs are a single cell suspension containing all cells from a tumor specimen including immune cells, tumor cells and support cells. The high percentage of viable cells in these readily available vials can meet the needs of many research projects.
Primary tumor tissue is an integral part of therapeutic and diagnostic research, but the logistics and budgetary challenges of obtaining fresh tissues can often lead to significant delays for research projects. The purpose of DTCs is to serve as a viable alternative to acquiring fresh tumor tissue. DTCs can be acquired quickly from our inventory, selected by many solid tumor indications and unique patient donors, and are more cost effective than acquiring fresh tissue and working through dissociation protocols in house. These viable single cell suspensions are useful for many of the same downstream applications as fresh tissue. DTCs contain all of the various cell populations present in the tumor microenvironment: tumor, immune and support cells.
Specific to I/O Research:
Conversant Bio now offers Gold Category DTCs. These samples have flow cytometry characterization reports available to aid in sample selection.
Note: View the Flow Cytometry Report for any DTCs with Flow Data sample by opening the inventory report, scrolling to the right and clicking the hyperlink for that sample's report.
Here's Dr. Shawn Fahl to tell you a little bit about the work he and his team have done evaluating our DTCs.
Submit this form to start a conversation with Conversant Bio to:
Conversant Bio wants to ensure that you will get the most out of your research with our samples. Our Sr. Researcher, Dr. Shawn Fahl, is available to work with you in many capacities:
One client who wished to remain anonymous because of the sensitive nature of their work recently said:
"We are clearly able to detect viable myeloid populations in the renal cell carcinoma DTCs. There appears to be fairly similar distributions across the three samples which is great. We’re showing T cell, B cell, NK, Monocyte and Neutrophil percentages of CD45+ viable cells."